India could reap the benefits of new targetted cancer therapy provided its drug control authority allows the import of expensive cancer drugs an expert said on Sunday. Drugs like Imatinib and molecules like monoclonal antibodies - made by identical immune cells - are being increasingly deployed across the world to attack cancer cells specifically without causing harm to normal body cells. In India these advanced therapeutic agents prove really expensive and their official access would cut down costs. 'The side-effects are much lower than traditional therapy agents. But some of the latest medicines antibodies and small molecules are really expensive.